Advertisement

Feasibility of Global Assessment of Bone Metastases in Prostate Cancer with 18F-Sodium Fluoride-PET/Computed Tomography

  • Author Footnotes
    1 These authors contributed equally to this work.
    Benjamin Koa
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    William Y. Raynor
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA

    Department of Radiology, Rutgers Robert Wood Johnson Medical School, 1 Robert Wood Johnson Place, MEB #404, New Brunswick, NJ 08901, USA
    Search for articles by this author
  • Peter Sang Uk Park
    Affiliations
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA

    Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Austin J. Borja
    Affiliations
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA

    Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Sachi Singhal
    Affiliations
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA

    Department of Medicine, Crozer-Chester Medical Center, 1 Medical Center Boulevard, Upland, PA 19013, USA
    Search for articles by this author
  • Angie Kuang
    Affiliations
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Vincent Zhang
    Affiliations
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Thomas J. Werner
    Affiliations
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Abass Alavi
    Affiliations
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Mona-Elisabeth Revheim
    Correspondence
    Corresponding author. Institute for Clinical Medicine, University of Oslo, Postbox 4950, Nydalen, Oslo 0424, Norway
    Affiliations
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA

    Division of Radiology and Nuclear Medicine, Oslo University Hospital, Sognsvannsveien 20, Oslo 0372, Norway

    Institute for Clinical Medicine, University of Oslo, Postbox 4950, Nydalen, Oslo 0424, Norway
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to PET Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Barsouk A.
        • Padala S.A.
        • Vakiti A.
        • et al.
        Epidemiology, staging and management of prostate cancer.
        Med Sci Basel Switz. 2020; 8https://doi.org/10.3390/medsci8030028
        • Damodaran S.
        • Kyriakopoulos C.E.
        • Jarrard D.F.
        Newly diagnosed metastatic prostate cancer: has the paradigm changed?.
        Urol Clin North Am. 2017; 44: 611-621
        • Macedo F.
        • Ladeira K.
        • Pinho F.
        • et al.
        Bone metastases: an overview.
        Oncol Rev. 2017; 11https://doi.org/10.4081/oncol.2017.321
        • Cook G.J.
        • Goh V.
        Functional and hybrid imaging of bone metastases.
        J Bone Miner Res. 2018; 33: 961-972https://doi.org/10.1002/jbmr.3444
        • Langsteger W.
        • Rezaee A.
        • Pirich C.
        • et al.
        18F-NaF-PET/CT and 99mTc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer.
        Semin Nucl Med. 2016; 46: 491-501
        • Bastawrous S.
        • Bhargava P.
        • Behnia F.
        • et al.
        Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice.
        RadioGraphics. 2014; 34: 1295-1316
        • Zhang V.
        • Koa B.
        • Borja A.J.
        • et al.
        Diagnosis and monitoring of osteoporosis with total-body 18F-sodium fluoride-PET/CT.
        PET Clin. 2020; 15: 487-496
        • Raynor W.Y.
        • Borja A.J.
        • Rojulpote C.
        • et al.
        18F-sodium fluoride: an emerging tracer to assess active vascular microcalcification.
        J Nucl Cardiol. 2020; https://doi.org/10.1007/s12350-020-02138-9
        • Mayer M.
        • Borja A.J.
        • Hancin E.C.
        • et al.
        Imaging atherosclerosis by PET, with emphasis on the role of FDG and NaF as potential biomarkers for this disorder.
        Front Physiol. 2020; 11https://doi.org/10.3389/fphys.2020.511391
        • Farolfi A.
        • Hadaschik B.
        • Hamdy F.C.
        • et al.
        Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary radical treatment: a systematic review.
        Eur Urol Oncol. 2021; 4: 714-730
        • Hillner B.E.
        • Siegel B.A.
        • Hanna L.
        • et al.
        18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry.
        J Nucl Med. 2015; 56: 222-228
        • Etchebehere E.C.
        • Araujo J.C.
        • Fox P.S.
        • et al.
        Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival.
        J Nucl Med. 2015; 56: 1177-1184https://doi.org/10.2967/jnumed.115.158626
        • Høilund-Carlsen P.F.
        • Edenbrandt L.
        • Alavi A.
        Global disease score (GDS) is the name of the game.
        Eur J Nucl Med Mol Imaging. 2019; 46: 1768-1772https://doi.org/10.1007/s00259-019-04383-8
        • Hofheinz F.
        • Pötzsch C.
        • Oehme L.
        • et al.
        Automatic volume delineation in oncological PET. evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets.
        Nukl Nucl Med. 2012; 51: 9-16https://doi.org/10.3413/Nukmed-0419-11-07
        • Wassberg C.
        • Lubberink M.
        • Sörensen J.
        • et al.
        Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases.
        EJNMMI Res. 2017; 7https://doi.org/10.1186/s13550-017-0289-9
        • Hofheinz F.
        • Langner J.
        • Petr J.
        • et al.
        A method for model-free partial volume correction in oncological PET.
        EJNMMI Res. 2012; 2: 16https://doi.org/10.1186/2191-219X-2-16
        • Torigian D.A.
        • Lopez R.F.
        • Alapati S.
        • et al.
        Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT.
        Hell J Nucl Med. 2011; 14: 8-14
        • Vanderhoek M.
        • Perlman S.B.
        • Jeraj R.
        Impact of the definition of peak standardized uptake value on quantification of treatment response.
        J Nucl Med. 2012; 53: 4-11https://doi.org/10.2967/jnumed.111.093443
        • Letellier A.
        • Johnson A.C.
        • Kit N.H.
        • et al.
        Uptake of radium-223 dichloride and early [18F]NaF PET response are driven by baseline [18F]NaF parameters: a pilot study in castration-resistant prostate cancer patients.
        Mol Imaging Biol. 2018; 20: 482-491
        • Zirakchian Zadeh M.
        • Østergaard B.
        • Raynor W.Y.
        • et al.
        Comparison of 18F-sodium fluoride uptake in the whole bone, pelvis, and femoral neck of multiple myeloma patients before and after high-dose therapy and conventional-dose chemotherapy.
        Eur J Nucl Med Mol Imaging. 2020; 47: 2846-2855https://doi.org/10.1007/s00259-020-04768-0
        • Brito A.E.
        • Santos A.
        • Sasse A.D.
        • et al.
        18 F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer.
        Oncotarget. 2017; 8: 36001-36011
        • Zadeh M.Z.
        • Raynor W.Y.
        • Seraj S.M.
        • et al.
        Evolving roles of fluorodeoxyglucose and sodium fluoride in assessment of multiple myeloma patients: introducing a novel method of pet quantification to overcome shortcomings of the existing approaches.
        PET Clin. 2019; 14: 341-352
        • Zadeh M.Z.
        • Seraj S.M.
        • Østergaard B.
        • et al.
        Prognostic significance of 18F-sodium fluoride in newly diagnosed multiple myeloma patients.
        Am J Nucl Med Mol Imaging. 2020; 10: 151-160
        • Yu E.Y.
        • Duan F.
        • Muzi M.
        • et al.
        Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
        J Nucl Med. 2015; 56: 354-360
        • Cook G.J.
        • Parker C.
        • Chua S.
        • et al.
        18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin).
        EJNMMI Res. 2011; 1: 4https://doi.org/10.1186/2191-219X-1-4
        • Mori K.
        • Janisch F.
        • Parizi M.K.
        • et al.
        Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis.
        Int J Clin Oncol. 2020; 25: 247-257
        • Fizazi K.
        • Massard C.
        • Smith M.
        • et al.
        Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer.
        Eur Urol. 2015; 68: 42-50
        • Chi K.N.
        • Kheoh T.
        • Ryan C.J.
        • et al.
        A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
        Ann Oncol. 2016; 27: 454-460
        • Guinney J.
        • Wang T.
        • Laajala T.D.
        • et al.
        Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
        Lancet Oncol. 2017; 18: 132-142
        • Halabi S.
        • Lin C.Y.
        • Kelly W.K.
        • et al.
        Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
        J Clin Oncol. 2014; 32: 671-677
        • D’Oronzo S.
        • Brown J.
        • Coleman R.
        The value of biomarkers in bone metastasis.
        Eur J Cancer Care (Engl). 2017; 26https://doi.org/10.1111/ecc.12725
        • Li D.
        • Lv H.
        • Hao X.
        • et al.
        Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis.
        Cancer Manag Res. 2018; 10: 3125-3139
        • Koo K.C.
        • Park S.U.
        • Kim K.H.
        • et al.
        Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels.
        Prostate Int. 2015; 3: 10-15
        • Lojanapiwat B.
        • Anutrakulchai W.
        • Chongruksut W.
        • et al.
        Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.
        Prostate Int. 2014; 2: 133-139
        • Jadvar H.
        • Desai B.
        • Ji L.
        • et al.
        Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.
        Clin Nucl Med. 2012; 37: 637-643
        • Sarikaya I.
        • Sarikaya A.
        • Elgazzar A.H.
        • et al.
        Prostate-specific antigen cutoff value for ordering sodium fluoride positron emission tomography/computed tomography bone scan in patients with prostate cancer.
        World J Nucl Med. 2018; 17: 281-285
        • Mabray M.C.
        • Brus-Ramer M.
        • Behr S.C.
        • et al.
        (18)F-Sodium fluoride PET-CT hybrid imaging of the lumbar facet joints: tracer uptake and degree of correlation to CT-graded arthropathy.
        World J Nucl Med. 2016; 15: 85-90
        • Spirig J.M.
        • Hüllner M.
        • Cornaz F.
        • et al.
        18F-Fluoride PET/MR for painful lumbar facet joint degeneration - a randomized controlled clinical trial.
        Spine J. 2021; https://doi.org/10.1016/j.spinee.2021.11.014
        • Wolff J.M.
        • Zimny M.
        • Borchers H.
        • et al.
        Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?.
        Eur Urol. 1998; 33: 376-381
        • Panagiotidis E.
        • Lam K.
        • Mistry A.
        • et al.
        Skeletal metastases and benign mimics on NaF PET/CT: a pictorial review.
        AJR Am J Roentgenol. 2018; 211: W64-W74https://doi.org/10.2214/AJR.17.19110
        • Lin C.
        • Bradshaw T.
        • Perk T.
        • et al.
        Repeatability of quantitative 18F-NaF PET: a multicenter study.
        J Nucl Med. 2016; 57: 1872-1879
        • Muzahir S.
        • Jeraj R.
        • Liu G.
        • et al.
        Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients.
        Am J Nucl Med Mol Imaging. 2015; 5: 162-168
        • Perk T.
        • Bradshaw T.
        • Chen S.
        • et al.
        Automated classification of benign and malignant lesions in 18F-NaF PET/CT images using machine learning.
        Phys Med Biol. 2018; 63: 225019
        • Polymeri E.
        • Kjölhede H.
        • Enqvist O.
        • et al.
        Artificial intelligence-based measurements of PET/CT imaging biomarkers are associated with disease-specific survival of high-risk prostate cancer patients.
        Scand J Urol. 2021; 55: 427-433